Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factor V Leiden: should we screen oral contraceptive users and pregnant women?

BMJ (Clinical research ed.) - 2 Nov 1996

Vandenbroucke J P, van der Meer F J, Helmerhorst F M, Rosendaal F R

Abstract excerpt

The factor V Leiden mutation is the most common genetic risk factor for deep vein thrombosis: it is present in about 5% of the white population. The risk of deep vein thrombosis among women who use oral contraceptives is greatly increased by the presence of the mutation. The same seems to be true of the risk of postpartum thrombosis. Several authors have called for all women to be screened before prescription of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Factor V
Share to Genetic Testing
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pedigree

Share to Pregnancy

Share to Prevalence

Share to Risk Assessment

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 8916702
DOI: 10.1136/bmj.313.7065.1127
PMCID: PMC2352463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factor V Leiden: should we screen oral contraceptive users and pregnant women?PMID 8916702Read ↗

Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?Semantic proximity Read ↗

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.Semantic proximity Read ↗

Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.Semantic proximity Read ↗

Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women.Semantic proximity Read ↗

Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations.Semantic proximity Read ↗

Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?Semantic proximity Read ↗

Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy.Semantic proximity Read ↗

Screening for factor V Leiden mutation before prescribing combination oral contraceptives.Semantic proximity Read ↗

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.Semantic proximity Read ↗

The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis.Semantic proximity Read ↗

Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.Semantic proximity Read ↗

Oral contraception in women with mild thrombophilia: what have we learned recently?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.